[HTML][HTML] ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
S Cang, C Iragavarapu, J Savooji, Y Song… - Journal of hematology & …, 2015 - Springer
With the advent of new agents targeting CD20, Bruton's tyrosine kinase, and
phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist …
phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist …
[PDF][PDF] ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
S Cang, C Iragavarapu, J Savooji, Y Song, D Liu - 2015 - researchgate.net
With the advent of new agents targeting CD20, Bruton's tyrosine kinase, and
phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist …
phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist …
[HTML][HTML] ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
S Cang, C Iragavarapu… - … of Hematology & …, 2015 - jhoonline.biomedcentral.com
With the advent of new agents targeting CD20, Bruton's tyrosine kinase, and
phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist …
phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist …
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.
S Cang, C Iragavarapu, J Savooji, Y Song… - Journal of Hematology …, 2015 - europepmc.org
With the advent of new agents targeting CD20, Bruton's tyrosine kinase, and
phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist …
phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist …
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
S Cang, C Iragavarapu, J Savooji… - … of Hematology & …, 2015 - search.proquest.com
With the advent of new agents targeting CD20, Bruton's tyrosine kinase, and
phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist …
phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist …
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.
S Cang, C Iragavarapu, J Savooji… - … of Hematology & …, 2015 - search.ebscohost.com
With the advent of new agents targeting CD20, Bruton's tyrosine kinase, and
phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist …
phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist …
[PDF][PDF] ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
S Cang, C Iragavarapu, J Savooji, Y Song, D Liu - 2015 - cyberleninka.org
With the advent of new agents targeting CD20, Bruton's tyrosine kinase, and
phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist …
phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist …
[引用][C] ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
S Cang, C Iragavarapu, J Savooji, Y Song… - Journal of Hematology & …, 2015 - cir.nii.ac.jp
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development | CiNii Research CiNii
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
[HTML][HTML] ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
S Cang, C Iragavarapu, J Savooji… - Journal of Hematology …, 2015 - ncbi.nlm.nih.gov
With the advent of new agents targeting CD20, Bruton's tyrosine kinase, and
phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist …
phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist …
[PDF][PDF] ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
S Cang, C Iragavarapu, J Savooji, Y Song, D Liu - 2015 - scienceopen.com
With the advent of new agents targeting CD20, Bruton's tyrosine kinase, and
phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist …
phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist …